<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02340182</url>
  </required_header>
  <id_info>
    <org_study_id>NL42072.018.12</org_study_id>
    <secondary_id>2012_283</secondary_id>
    <nct_id>NCT02340182</nct_id>
  </id_info>
  <brief_title>The Role of the Microbiota in the Systemic Immune Response</brief_title>
  <acronym>MISSION-1</acronym>
  <official_title>The Role of the Microbiota in the Systemic Immune Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.J. Wiersinga, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the role of the gut microbiota in the systemic&#xD;
      priming of immune effector cells. Twelve healthy male volunteers, 18-35 years of age, will be&#xD;
      treated with broad spectrum antibiotics (ciprofloxacin, vancomycin, metronidazole) for seven&#xD;
      days, in order to deplete the gut microbiota. Blood and faeces will be sampled before, 24&#xD;
      hours and 6 weeks after the 7-day period of antibiotics. Main study endpoints include&#xD;
      laboratory parameters for inflammatory responses, functional assays (ex vivo stimulation&#xD;
      assay) and gut microbiota composition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Sepsis ranks among the top ten leading causes of death worldwide. Most&#xD;
      nonsurvivors die in a state of immunosuppression. The gut microbiota exerts numerous&#xD;
      beneficial functions in the host response against infections. Gut flora components express&#xD;
      microorganism-associated molecular patterns (MAMPs) such as lipopolysaccharide (LPS), which&#xD;
      are recognized by pattern recognition receptors (PRRs) expressed by neutrophils and&#xD;
      macrophages. MAMPs from the intestinal microbiota constitutively translocate to the&#xD;
      circulation and prime bone marrow derived neutrophils via PRRs. Antibiotic treatment, which&#xD;
      is standard of care for all patients with sepsis, depletes the gut microbiota and leads to a&#xD;
      diminished release of MAMPs and other bacteria derived products. This causes diminished&#xD;
      priming of systemic immunity, which may attribute to sepsis associated immunosuppression and&#xD;
      an increased susceptibility to invading bacteria.&#xD;
&#xD;
      Objective: To investigate the role of the gut microbiota in the systemic priming of immune&#xD;
      effector cells&#xD;
&#xD;
      Study design: Within-subject-controlled intervention study in human volunteers&#xD;
&#xD;
      Study population: Twelve healthy male subjects, 18-35 years of age&#xD;
&#xD;
      Intervention: All subjects will be treated with broad spectrum antibiotics (ciprofloxacin,&#xD;
      vancomycin, metronidazole) for seven days, in order to deplete the gut microbiota. Blood and&#xD;
      faeces will be sampled before, 24 hours and 6 weeks after the 7-day period of antibiotics.&#xD;
&#xD;
      Main study parameters/endpoints: Laboratory parameters for inflammatory responses, functional&#xD;
      assays (ex vivo stimulation assay) and gut microbiota composition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite measure of Laboratory parameters for inflammatory responses.</measure>
    <time_frame>up to 7 weeks</time_frame>
    <description>Ex vivo response of whole blood, isolated monocytes or neutrophils to lipopolysaccharide.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Side effects will be registered using a graded scale</measure>
    <time_frame>up to week 7</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>A HITchip (human intestinal tract chip; 16S rRNA) analysis will be used to determine microbiome composition</measure>
    <time_frame>up to week 7</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Antibiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All volunteers will self-administer the following antibiotics for 7 consecutive days (concomitantly):&#xD;
Vancomycin 250mg 3dd2;&#xD;
Ciprofloxacin 500mg 2dd1;&#xD;
Metronidazole 500mg 3dd1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>250mg 3dd2</description>
    <arm_group_label>Antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>500mg 2dd1</description>
    <arm_group_label>Antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>500mg 3dd1</description>
    <arm_group_label>Antibiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy&#xD;
&#xD;
          -  Male between 18 and 35 years of age&#xD;
&#xD;
          -  Capable of giving written informed consent and able to comply with the requirements&#xD;
             and restrictions&#xD;
&#xD;
          -  Chemistry panel without any clinically relevant abnormality&#xD;
&#xD;
          -  Normal defecation pattern (defined as &lt;3x/ day and &gt;3x/week)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major illness in the past 3 months or significant chronic medical illness;&#xD;
&#xD;
          -  History of any type of malignancy;&#xD;
&#xD;
          -  Past or current gastrointestinal disease which may influence the gut microbiota;&#xD;
&#xD;
          -  Known positive test for hepatitis C antibody, hepatitis B surface antigen or HIV;&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary&#xD;
             abnormalities;&#xD;
&#xD;
          -  Use of tobacco products;&#xD;
&#xD;
          -  History, within 3 years, of drug abuse;&#xD;
&#xD;
          -  History of alcoholism and/or drinking more than 3 units of alcohol per day;&#xD;
&#xD;
          -  The subject has received an investigational product within three months of day 1;&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs and herbal and dietary supplements&#xD;
             within 6 months;&#xD;
&#xD;
          -  Recent (&lt; 12 months) use of antibiotics (any kind, except for dermal antibiotics);&#xD;
&#xD;
          -  Allergy to antibiotics (any kind);&#xD;
&#xD;
          -  Difficulty swallowing pills;&#xD;
&#xD;
          -  Any other relevant issue.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Van der Poll, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>July 8, 2013</study_first_submitted>
  <study_first_submitted_qc>January 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2015</study_first_posted>
  <last_update_submitted>January 15, 2015</last_update_submitted>
  <last_update_submitted_qc>January 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>W.J. Wiersinga, MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>gut flora</keyword>
  <keyword>antibiotics</keyword>
  <keyword>systemic immune response</keyword>
  <keyword>Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

